Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations

Medientyp: E-Artikel

Titel: Clinical and histopathological features of myeloid neoplasms with concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V mutations

Beteiligte: Naumann, Nicole [Verfasser:in]; Lübke, Johannes [Verfasser:in]; Shomali, William [Verfasser:in]; Reiter, Lukas [Verfasser:in]; Horny, Hans-Peter [Verfasser:in]; Jawhar, Mohamad [Verfasser:in]; Dangelo, Vito [Verfasser:in]; Fabarius, Alice [Verfasser:in]; Metzgeroth, Georgia [Verfasser:in]; Kreil, Sebastian [Verfasser:in]; Sotlar, Karl [Verfasser:in]; Oni, Claire [Verfasser:in]; Harrison, Claire [Verfasser:in]; Hofmann, Wolf-Karsten [Verfasser:in]; Cross, Nicholas C. P. [Verfasser:in]; Valent, Peter [Verfasser:in]; Radia, Deepti [Verfasser:in]; Gotlib, Jason [Verfasser:in]; Reiter, Andreas [Verfasser:in]; Schwaab, Juliana [Verfasser:in]

Erschienen: 1 June 2021

Sprache: Englisch

DOI: 10.1111/bjh.17567

Identifikator:

Schlagwörter: JAK2 V617F ; KIT D816V ; mixed phenotype ; multi-mutated myeloid neoplasm ; myeloproliferative neoplasm ; systemic mastocytosis

Entstehung:

Anmerkungen:

Beschreibung: We report on 45 patients with myeloid neoplasms and concurrent Janus kinase 2 (JAK2) V617F and KIT proto-oncogene, receptor tyrosine kinase (KIT) D816V (JAK2pos./KITpos.) mutations, which are individually identified in >60% of patients with classical myeloproliferative neoplasms (MPN) and >90% of patients with systemic mastocytosis (SM) respectively. In SM, the concurrent presence of a clonal non-mast cell neoplasm [SM with associated haematological neoplasm (SM-AHN)] usually constitutes a distinct subtype associated with poor survival. All 45 patients presented with a heterogeneous combination of clinical/morphological features typical of the individual disorders (e.g. leuco-/erythro-/thrombocytosis and elevated lactate dehydrogenase for MPN; elevated serum tryptase and alkaline phosphatase for SM). Overlapping features identified in 70% of patients included splenomegaly, cytopenia(s), bone marrow fibrosis and additional somatic mutations. Molecular dissection revealed discordant development of variant allele frequency for both mutations and absence of concurrently positive single-cell derived colonies, indicating disease evolution in two independent clones rather than monoclonal disease in >60% of patients examined. Overall survival of JAK2pos./KITpos. patients without additional somatic high-risk mutations [HRM, e.g. in serine and arginine-rich splicing factor 2 (SRSF2), additional sex combs like-1 (ASXL1) or Runt-related transcription factor 1 (RUNX1)] at 5 years was 77%, indicating that the mutual impact of JAK2 V617F and KIT D816V on prognosis is fundamentally different from the adverse impact of additional HRM in the individual disorders.

Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: